Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 3/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24595495 | 1.00 | SIGMAR1 (0.83) | SIGMAR1CYP1A2ALDH1A1TSHRPKM | |
| SCHEMBL19681594 | 1.00 | SIGMAR1 (0.83) | SIGMAR1CYP1A2ALDH1A1TSHRPKM | |
| SCHEMBL10324648 | 0.98 | SIGMAR1 (0.79) | SIGMAR1CYP1A2ALDH1A1TSHRPKM | |
| SCHEMBL10324713 | 0.93 | SIGMAR1 (0.96) | SIGMAR1CYP1A2ALDH1A1TSHRKDM5A | |
| SCHEMBL10325527 | 0.93 | SIGMAR1 (0.72) | SIGMAR1CYP1A2ALDH1A1TSHRKDM5A | |
| SCHEMBL10438441 | 0.91 | SIGMAR1 (1.00) | SIGMAR1CYP1A2ALDH1A1TSHRKDM5A | |
| SCHEMBL10438376 | 0.91 | SIGMAR1 (1.00) | SIGMAR1CYP1A2ALDH1A1TSHRKDM5A | |
| SCHEMBL10451607 | 0.91 | SIGMAR1 (1.00) | SIGMAR1CYP1A2ALDH1A1TSHRKDM5A | |
| SCHEMBL10438445 | 0.91 | SIGMAR1 (1.00) | SIGMAR1CYP1A2ALDH1A1TSHRKDM5A | |
| SCHEMBL10456237 | 0.91 | SIGMAR1 (1.00) | SIGMAR1CYP1A2ALDH1A1TSHRKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115141153-A | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2022-10-04 | — | — | CN | claimed |
| EP-2663400-A1 | PROCESS OF MAKING MODIFIED METALLOCENE CATALYST, CATALYST PRODUCED AND USE THEREOF | W. R. Grace & Co.-Conn (US) | 2013-11-20 | — | — | EP | claimed |
| WO-2012097146-A1 | PROCESS OF MAKING MODIFIED METALLOCENE CATALYST, CATALYST PRODUCED AND USE THEREOF | W. R. GRACE & CO.-CONN. (US) | 2012-07-19 | — | — | WO | claimed |
| CN-115141153-B | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2023-11-14 | — | — | CN | disclosed |
| CN-115141153-A | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2022-10-04 | — | — | CN | disclosed |
| EP-2663400-A1 | PROCESS OF MAKING MODIFIED METALLOCENE CATALYST, CATALYST PRODUCED AND USE THEREOF | W. R. Grace & Co.-Conn (US) | 2013-11-20 | — | — | EP | disclosed |
| WO-2012097146-A1 | PROCESS OF MAKING MODIFIED METALLOCENE CATALYST, CATALYST PRODUCED AND USE THEREOF | W. R. GRACE & CO.-CONN. (US) | 2012-07-19 | — | — | WO | disclosed |
| EP-1768966-B1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-0385686-A2 | Compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |